Introduction
AI Overview · plain answer
PARP inhibitors and Lu-177 PSMA therapy are both used in advanced (metastatic castration-resistant) prostate cancer, but they are chosen for different patients: PARP inhibitors for men with a BRCA or other HRR gene mutation, Lu-177 PSMA for men whose disease is PSMA-positive on a PET scan. Their side effects overlap and differ. Both commonly cause anaemia, marrow suppression and fatigue. PARP inhibitors add nausea, appetite loss, a risk of blood clots, and a small long-term risk of MDS/AML (a blood cancer). Lu-177 PSMA adds a distinctive dry mouth, needs kidney monitoring, and involves short radiation-safety precautions. Neither is simply “safer” — the right choice depends on the individual.
Men with advanced prostate cancer and their families often ask a reasonable question: of the newer targeted treatments, which is gentler? When the two being compared are a PARP inhibitor and Lu-177 PSMA radioligand therapy, the honest answer is that they are not really rivals for the same seat — and their side-effect profiles differ in kind. This article lays both out side by side, with the numbers from their main trials, so the comparison is concrete rather than vague.
Important
This is general medical information for education, not medical advice. Side-effect rates quoted are from clinical trials and prescribing information and describe groups of patients, not any one person. Whether either treatment is appropriate — and in what order — depends on the individual’s genetic testing, PSMA-PET imaging, prior treatment and organ function, and is decided in a multidisciplinary review.
First, the key point: these are not simple alternatives
Before comparing side effects, it matters why a patient is offered one or the other. The two are selected by different biomarkers:
- PARP inhibitors work by “synthetic lethality” in cancer cells that already have a faulty DNA-repair system. They are used in men whose tumour carries a mutation in a homologous-recombination-repair (HRR) gene — most importantly BRCA1/2 — confirmed by genetic testing.[2][3]
- Lu-177 PSMA delivers targeted radiation to cells that carry the PSMA protein. It is used in men whose disease is PSMA-positive on a PSMA-PET scan.[1][6]
A given patient may qualify for one, for both, or for neither. So “PARP versus Lu-177” is rarely a straight either/or decision — it is usually a question of which target the patient’s cancer presents, and which makes most sense at that point in their treatment.[7] With that established, here is how the toxicity of each looks.
PARP inhibitor (olaparib / Lynparza) side effects
The PARP-inhibitor class includes olaparib (sold as Lynparza), rucaparib, niraparib and talazoparib; olaparib has the most prostate-cancer data, from the PROfound trial. They are oral tablets (olaparib is 300 mg twice daily) taken continuously.[3] The side effects of olaparib are reasonably consistent across the PARP class, so the profile below is broadly representative of olaparib and Lynparza side effects.
The defining one is anaemia — low haemoglobin is a recognised class effect and the single most common side effect. In olaparib trials it affected roughly 46–50% of patients, with about a third of those events severe (grade 3 or higher), and it was the leading reason patients stopped treatment (about 7%).[2][4] The next most common are nausea (43%), fatigue (42%) and reduced appetite (31%), mostly mild-to-moderate and tending to peak in the first two months.[4] Blood tests frequently show drops in haemoglobin, white cells and platelets.
Three less common but important risks define the class:
- Blood clots (venous thromboembolism / pulmonary embolism) — about 7–8% with olaparib versus ~3% with the comparator in PROfound.[3][4]
- MDS/AML — a small but real long-term risk of myelodysplastic syndrome or acute myeloid leukaemia. The evidence supports a causal link, but the incidence in prostate cancer is low: under 1.5%, and 0.4% in PROfound.[4]
- Pneumonitis (lung inflammation) — uncommon, about 2%.[4]
Overall, grade 3-or-higher side effects occurred in about 51% of olaparib patients in PROfound, versus ~38% on the hormonal comparator.[2]
| PARP inhibitors — at a glance | |
|---|
| Route | Oral tablet, continuous (olaparib 300 mg twice daily) |
| Most common | Anaemia (~46–50%), nausea (~43%), fatigue (~42%), reduced appetite (~31%) |
| Grade ≥3 overall | ~51% (PROfound) |
| Distinctive risks | Blood clots (~7–8%), MDS/AML (<1.5%), pneumonitis (~2%) |
| Main monitoring | Regular blood counts; watch for clots and, rarely, lung symptoms |
Lu-177 PSMA (Pluvicto) side effects
Lu-177 PSMA-617 (the radioligand marketed as Pluvicto) is given by intravenous infusion, typically 7.4 GBq every six weeks for four to six cycles.[1] Because it delivers short-range beta radiation directly to PSMA-bearing cells, Pluvicto side effects follow a different pattern from an oral tablet.
The defining one is dry mouth (xerostomia) — the salivary glands also take up PSMA, so they receive some radiation. Dry mouth occurred in 38.8% of patients in VISION and is almost always mild-to-moderate (grade 1–2).[1] The other common effects are fatigue (43.1%) and nausea (35.3%).[1]
Like PARP inhibitors, Lu-177 PSMA suppresses the bone marrow, but the specific risks differ:
- Marrow suppression — grade 3-or-higher anaemia (12.9%), thrombocytopenia (low platelets, 7.9%) and lymphopenia (7.8%) in VISION. The label carries a warning that myelosuppression can be severe.[1]
- Kidney monitoring — the kidneys clear the radioligand, so kidney function is monitored and hydration is used during treatment; in practice renal function is usually preserved.[1][5]
- Radiation-safety precautions — short, temporary measures after each dose (distance from young children and pregnant women, simple hygiene steps), explained beforehand.[1]
Overall, grade 3-or-higher side effects occurred in 52.7% of Lu-177 PSMA patients in VISION, versus 38.0% on standard care alone — with treatment discontinued for side effects in 11.9%.[1] Notably, in the PSMAfore trial the rate of severe and serious side effects was actually lower with Lu-177 PSMA than with a change of hormonal therapy, though dry mouth and anaemia were more common.[5]
| Lu-177 PSMA — at a glance | |
|---|
| Route | IV infusion, ~every 6 weeks, 4–6 cycles |
| Most common | Fatigue (43.1%), dry mouth (38.8%, mostly mild), nausea (35.3%) |
| Grade ≥3 overall | 52.7% (VISION) |
| Distinctive features | Dry mouth from salivary uptake; radiation-safety precautions; kidney monitoring |
| Main monitoring | Blood counts and kidney function; salivary-gland care |
Side by side
| | PARP inhibitors | Lu-177 PSMA |
|---|
| Chosen for | HRR / BRCA mutation (genetic test) | PSMA-positive disease (PSMA-PET) |
| How given | Oral tablet, daily | IV infusion, every 6 weeks |
| Shared effects | Anaemia · marrow suppression · fatigue |
| Distinctive effects | Nausea, appetite loss | Dry mouth (salivary) |
| Serious / long-term | Blood clots; MDS/AML (<1.5%); pneumonitis | Severe myelosuppression; radiation precautions |
| Key monitoring | Blood counts; clot & lung watch | Blood counts; kidney function |
| Grade ≥3 overall | ~51% (PROfound) | 52.7% (VISION) |
What’s the same, and what’s different
The honest summary is that the burden of severe side effects is broadly similar — the headline grade 3-plus rates (~51% for olaparib, 52.7% for Lu-177 PSMA) sit close together, and both are above their respective comparators at ~38%.[1][2] What separates them is the type of risk:
- Shared: anaemia, marrow suppression and fatigue are common to both and call for blood-count monitoring either way.
- PARP-specific: gastrointestinal effects (nausea, appetite loss), a risk of blood clots, and a small but defining long-term risk of MDS/AML.
- Lu-177-specific: a characteristic dry mouth, kidney monitoring, and temporary radiation-safety precautions — with no MDS/AML signal of the kind seen with PARP inhibitors.
So a man particularly worried about a long-term blood-cancer risk, or who is prone to clots, may weigh the PARP profile differently; a man for whom a persistent dry mouth would be especially troublesome may weigh the Lu-177 profile differently. These are conversations to have with the treating team — not reasons to rule either out in the abstract.
Can they be used together, or one after the other?
Because both treatments work by damaging tumour DNA, they may share some resistance pathways, and researchers are still studying the best sequence.[8] In practice, a patient who qualifies for both may receive them one after the other, and the order is decided case by case — taking into account blood counts (since both suppress the marrow), prior treatments, and how the disease is behaving.[7] Stacking marrow-suppressing treatments needs care, which is exactly why these decisions belong in a multidisciplinary review rather than a simple ranking of “which is safer.”
"Patients often want a single answer to ‘which is gentler.’ The truthful answer is that PARP inhibitors and Lu-177 PSMA carry a similar overall burden but a different shape of risk — and they are usually chosen by the cancer’s biology, not by side effects alone."
Dr. Ishita B. Sen · Director & Chief, Nuclear Medicine, FMRI
Second Read · review of your case
If you or a family member is weighing a PARP inhibitor against Lu-177 PSMA therapy, the nuclear medicine team at FMRI — Dr. Ishita B. Sen and Dr. Dharmender Malik — can review your genetic testing, PSMA-PET and reports and explain which options realistically apply, and what each would involve.
Request a Second Read · WhatsApp +91 8800 988936
For patients & families
Frequently asked questions
Q01Which has worse side effects — PARP inhibitors or Lu-177 PSMA therapy?
Neither is simply safer. In their pivotal trials the rate of severe (grade 3 or higher) side effects was broadly similar — about 51% with olaparib in PROfound and about 53% with Lu-177 PSMA in VISION, versus about 38% with the comparators. What differs is the kind of side effect. Both cause anaemia, marrow suppression and fatigue. PARP inhibitors add nausea and appetite loss, a risk of blood clots, and a small long-term risk of MDS/AML. Lu-177 PSMA adds a distinctive dry mouth, needs kidney monitoring, and involves short radiation-safety precautions. The right choice depends on the individual.
Q02Do both PARP inhibitors and Lu-177 PSMA cause anaemia?
Yes. Anaemia is common with both. For PARP inhibitors it is a recognised class effect and the most common side effect — around 46–50% of patients in olaparib trials, with roughly a third of those events severe, and it is the leading reason patients stop the drug. With Lu-177 PSMA, anaemia of grade 3 or higher occurred in about 13% of patients in VISION. Both are managed with blood-count monitoring and, where needed, transfusion or dose adjustment.
Q03What is the dry mouth caused by Lu-177 PSMA therapy?
Lu-177 PSMA is taken up not only by prostate-cancer cells but also by the salivary glands, which can cause a dry mouth (xerostomia). It was reported in about 39% of patients in the VISION trial and is almost always mild to moderate (grade 1–2). It is a distinctive feature of this therapy and is not seen with PARP inhibitors.
Q04Do PARP inhibitors cause leukaemia (MDS or AML)?
There is a small but real long-term risk. Across the olaparib programme the evidence supports a causal relationship with myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML), but the incidence in men with prostate cancer is low — under 1.5%, and 0.4% in the PROfound trial. It is one reason long-term blood-count monitoring is important. This specific MDS/AML signal is characteristic of the PARP-inhibitor class.
Q05Are PARP inhibitors and Lu-177 PSMA alternatives to each other?
Not simply. They are selected for different patients. PARP inhibitors are for men whose tumour carries a mutation in a homologous-recombination-repair (HRR) gene, such as BRCA1/2 — confirmed by genetic testing. Lu-177 PSMA is for men whose disease is PSMA-positive on a PSMA-PET scan. A patient may qualify for one, both or neither, and the order in which they are used is an individual decision.
Q06Is the radiation from Lu-177 PSMA dangerous to my family?
Lu-177 emits short-range beta radiation and patients are usually treated as outpatients. For a short period after each dose, simple precautions are advised — keeping some distance from young children and pregnant women, and following the team’s instructions on bathroom hygiene and laundry. These precautions are temporary and are explained before treatment. PARP inhibitors are oral tablets and involve no radiation precautions.
Q07Can PARP inhibitors and Lu-177 PSMA be used together or one after the other?
Both damage tumour DNA, so they may share some resistance pathways, and the best sequence is still being studied. In practice they are sometimes used one after the other when a patient qualifies for both. Whether to combine or sequence them, and in what order, is decided case by case in a multidisciplinary review, taking blood counts and prior treatment into account.
Q08How are the side effects of these treatments monitored and managed?
Both require regular blood tests to watch for anaemia and low platelets or white cells. PARP inhibitors are managed mainly with dose interruptions, dose reductions, and treatment of anaemia; patients are also watched for blood clots and, rarely, lung inflammation. Lu-177 PSMA involves blood-count and kidney-function monitoring, salivary-gland care for dry mouth, and standard anti-nausea support. Most side effects of both are manageable and reversible.
Evidence & references
Figures in this article are taken from the following peer-reviewed trials, regulatory approvals and prescribing information. Open each in a new tab to read the source.
[1] VISION — Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[2] PROfound — de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2020;382(22):2091-2102.
View source ↗[3] FDA — Approval of olaparib (Lynparza) for HRR gene-mutated mCRPC. U.S. Food & Drug Administration, 2020.
View source ↗[4] Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. Olaparib tolerability and common adverse-event management in mCRPC: further analyses from PROfound.
Eur J Cancer. 2022.
View source ↗[5] PSMAfore — Final overall survival and safety analyses of [177Lu]Lu-PSMA-617 versus change of ARPI in taxane-naïve mCRPC.
Ann Oncol. 2025.
View source ↗[6] FDA — Approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive mCRPC. U.S. Food & Drug Administration.
View source ↗[7] Emerging Therapeutic Strategies in Prostate Cancer: PARP inhibition, PSMA-directed therapy and AR blockade — patient selection & sequencing review.
J Clin Med. 2026.
View source ↗[8] Association of prior PARP-inhibitor exposure with outcomes after 177Lu-PSMA-617 in HRR-mutated mCRPC.
Eur Urol Oncol. 2025.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · Director & Chief, Department of Nuclear Medicine, Fortis Memorial Research Institute
Dr. Sen leads the nuclear medicine and theranostics programme at FMRI, Gurugram, with a focus on PSMA and DOTATATE imaging and Lu-177 and Ac-225 radioligand therapy. She works alongside Dr. Dharmender Malik on patient selection, dosimetry and the careful, evidence-based use of targeted therapies in advanced cancer.